Share
Dr. David Kideckel
Rakovina Therapeutics Inc., a biopharmaceutical company developing innovative cancer therapies through AI-powered drug discovery, has appointed Dr. David M. Kideckel, Ph.D., MBA, as Chief Financial Officer (CFO), subject to approval from the TSX Venture Exchange (“TSXV”).
Dr. Kideckel brings nearly 20 years of experience spanning life sciences, capital markets, and corporate advisory, with a proven record of helping public and private healthcare companies expand operations and enhance shareholder value. He is the Founder and Principal of Kideckel Advisory Group Inc., which provides fractional CFO, Chief Business Officer (CBO), and capital markets expertise to TSX- and Nasdaq-listed companies, as well as private corporations.
In addition, he serves as a Partner at Siskos & Associates, which has been engaged to deliver comprehensive back-office accounting services to Rakovina, including financial reporting.
Previously, Dr. Kideckel served as Managing Director, Head of Life Sciences, and Senior Institutional Equity Research Analyst at ATB Capital Markets. His earlier career includes leadership roles at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca PLC), where he contributed to strategic initiatives in drug development and commercialization.
Dr. Kideckel earned his Ph.D. in Neuroscience and Statistics from the University of Toronto’s Institute of Medical Science and his MBA from the Rotman School of Management.
